NASDAQ:IOSPInnospec Stock Price, Forecast & News

Innospec's stock was trading at $72.47 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IOSP shares have increased by 10.7% and is now trading at $80.20.
View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Innospec.

Innospec is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Innospec.

Innospec Inc. (NASDAQ:IOSP) released its quarterly earnings results on Tuesday, August, 4th. The specialty chemicals company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.49. The specialty chemicals company earned $244.90 million during the quarter, compared to the consensus estimate of $278.65 million. Innospec had a net margin of 3.96% and a return on equity of 11.10%. The business's quarterly revenue was down 32.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.12 EPS.
View Innospec's earnings history.

Innospec declared a semi-annual dividend on Thursday, May 7th. Shareholders of record on Monday, May 18th will be paid a dividend of $0.52 per share on Tuesday, May 26th. This represents a yield of 1.5%. The ex-dividend date of this dividend is Friday, May 15th.
View Innospec's dividend history.

1 brokerages have issued twelve-month target prices for Innospec's stock. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's share price to reach $95.00 in the next twelve months. This suggests a possible upside of 18.5% from the stock's current price.
View analysts' price targets for Innospec.

Headlines about IOSP stock have trended very positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innospec earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Innospec.

Innospec saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 445,800 shares, a decline of 17.6% from the July 15th total of 540,900 shares. Based on an average daily trading volume, of 114,000 shares, the days-to-cover ratio is presently 3.9 days. Approximately 1.8% of the shares of the stock are short sold.
View Innospec's Short Interest.

Some companies that are related to Innospec include Sherwin-Williams (SHW), Ecolab (ECL), International Flavors & Fragrances (IFF), Celanese (CE), RPM International (RPM), Albemarle (ALB), Ashland Global (ASH), NewMarket (NEU), Quaker Chemical (KWR), Balchem (BCPC), W. R. Grace & Co (GRA), Stepan (SCL), HB Fuller (FUL), PolyOne (POL) and Sensient Technologies (SXT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Altria Group (MO), NVIDIA (NVDA), Sherwin-Williams (SHW), Applied Materials (AMAT), Activision Blizzard (ATVI), Broadcom (AVGO), Boeing (BA), Caterpillar (CAT), Colgate-Palmolive (CL) and Clorox (CLX).

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec's stock is owned by a variety of retail and institutional investors. Top institutional investors include Principal Financial Group Inc. (0.78%), Kirr Marbach & Co. LLC IN (0.41%), Assenagon Asset Management S.A. (0.27%), Mutual of America Capital Management LLC (0.24%), Swiss National Bank (0.22%) and UBS Group AG (0.22%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon.
View institutional ownership trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Principal Financial Group Inc., First Trust Advisors LP, Mackay Shields LLC, Trexquant Investment LP, Strs Ohio, Kirr Marbach & Co. LLC IN, ZWJ Investment Counsel Inc., and Hancock Whitney Corp. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, and Philip John Boon.
View insider buying and selling activity for Innospec.

IOSP stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., UBS Group AG, Mutual of America Capital Management LLC, Swiss National Bank, WINTON GROUP Ltd, Grandfield & Dodd LLC, Pendal Group Ltd, and ProShare Advisors LLC.
View insider buying and selling activity for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $80.20.

Innospec has a market capitalization of $1.97 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe.

The official website for Innospec is www.innospecinc.com.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]